Jpmorgan Chase & CO Kamada LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KMDA
# of Institutions
36Shares Held
6.38MCall Options Held
2.2KPut Options Held
63.8K-
Phoenix Holdings Ltd. Givatayim, L31.83MShares$11 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$8.52 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny836KShares$5.01 Million0.01% of portfolio
-
Y.D. More Investments LTD Ramat Gan, L3710KShares$4.25 Million0.4% of portfolio
-
Wells Fargo & Company San Francisco, CA638KShares$3.82 Million0.0% of portfolio
About KAMADA LTD
- Ticker KMDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 44,800,500
- Market Cap $268M
- Description
- Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...